SB 24-203

Senate Bill 24-203, which has been approved by the governor and will take effect on August 7, 2024, requires the Colorado Prescription Drug Affordability Review Board to consider input from the Colorado Rare Disease Advisory Council when reviewing prescription drugs that are designated as orphan drugs for rare diseases. This means that the board must now listen to advice from experts and patients about these specific medications, which could help make such expensive treatments more affordable for people with rare conditions. The bill affects individuals living with rare diseases who rely on specialized medication.

Official Summary

Current law requires the Colorado prescription drug affordability review board (board) to take certain measures in determining whether to conduct an affordability review for an identified prescription drug. The act requires the board, in making such a determination, to consider whether the drug has an approved orphan drug designation for one or more rare diseases and no other indications and, if so, to consider input from consumers and the Colorado rare disease advisory council (council). Current law requires the board, in performing an affordability review, to consider certain information. The act requires the board to consider input from the council. APPROVED by Governor June 6, 2024 EFFECTIVE August 7, 2024(Note: This summary applies to this bill as enacted.)

Votes